InnoCan Pharma Corporation INNPF
OTC PK
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -18.79% | 29.61% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -18.79% | 29.61% | |||
| Cost of Revenue | -16.35% | 3.05% | |||
| Gross Profit | -19.03% | 32.96% | |||
| SG&A Expenses | -18.58% | 25.06% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -20.59% | 22.69% | |||
| Operating Income | 35.37% | 14.75% | |||
| Income Before Tax | 73.97% | -151.60% | |||
| Income Tax Expenses | -200.00% | 124.43% | |||
| Earnings from Continuing Operations | 83.07% | -147.76% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 234.88% | -161.43% | |||
| Net Income | 96.50% | -148.72% | |||
| EBIT | 35.37% | 14.75% | |||
| EBITDA | 35.35% | 14.51% | |||
| EPS Basic | 96.48% | -148.53% | |||
| Normalized Basic EPS | 100.16% | -175.16% | |||
| EPS Diluted | 96.48% | -148.53% | |||
| Normalized Diluted EPS | 100.16% | -175.16% | |||
| Average Basic Shares Outstanding | 0.00% | 0.41% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.41% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||